La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Australian Clinical Labs Dividende

Dividende contrôle des critères 1/6

Australian Clinical Labs is a dividend paying company with a current yield of 2.31%.

Informations clés

2.3%

Rendement du dividende

130%

Ratio de distribution

Rendement moyen de l'industrie	2.6%
Prochaine date de paiement du dividende	n/a
Date ex-dividende	n/a
Dividende par action	AU$0.060
Résultat par action	AU$0.077
Prévisions de rendement du dividende à 3 ans	5.8%

Mises à jour récentes des dividendes

Recent updates

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Aug 14

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 25

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

Dec 22

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Dec 21

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Sep 01

Stabilité et croissance des paiements

Récupération des données sur les dividendes

Dividende stable: ACL verse un dividende depuis moins de 10 ans et pendant cette période, les paiements ont été volatils.

Dividende croissant: ACL has only been paying a dividend for 2 years, and since then payments have fallen.

Rendement des dividendes par rapport au marché

Australian Clinical Labs Rendement des dividendes par rapport au marché

Comment le rendement du dividende de ACL se compare-t-il à celui du marché ?
Segment	Rendement du dividende
Entreprise (ACL)	2.3%
25% du marché (AU)	2.6%
25% du marché (AU)	6.1%
Moyenne du secteur (Healthcare)	2.6%
Prévisions des analystes dans 3 ans (ACL)	5.8%

Dividende notable: ACL's dividend (2.31%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.58%).

Dividende élevé: ACL's dividend (2.31%) is low compared to the top 25% of dividend payers in the Australian market (6.15%).

Bénéfice distribué aux actionnaires

Couverture des revenus: With its high payout ratio (129.9%), ACL's dividend payments are not well covered by earnings.

Paiement en espèces aux actionnaires

Couverture des flux de trésorerie: With its low cash payout ratio (8.2%), ACL's dividend payments are thoroughly covered by cash flows.

Australian Clinical Labs Dividende

Dividende contrôle des critères 1/6

Informations clés

Mises à jour récentes des dividendes

Upcoming dividend of AU$0.03 per share

Upcoming dividend of AU$0.07 per share at 4.6% yield

Australian Clinical Labs Limited Declares Full Year Fully Franked Dividend for the Fiscal Year 2023, Payable on 3 October 2023

Upcoming dividend of AU$0.07 per share at 13% yield

Australian Clinical Labs Limited Announces Dividend for the Six Months Ended December 31, 2022, Payable on April 26, 2023

Upcoming dividend of AU$0.41 per share

Recent updates

Australian Clinical Labs Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2024

We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt

Upcoming dividend of AU$0.03 per share

Consensus EPS estimates fall by 20%

First half dividend reduced to AU$0.03

First half 2024 earnings released: EPS: AU$0.025 (vs AU$0.13 in 1H 2023)

Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?

Australian Clinical Labs Limited to Report First Half, 2024 Results on Feb 28, 2024

Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?

Price target decreased by 7.5% to AU$3.56

Upcoming dividend of AU$0.07 per share at 4.6% yield

Consensus EPS estimates fall by 21%

Australian Clinical Labs Limited Announces Appointment of Christine Bartlett as Non-Executive Director

Australian Clinical Labs Limited Declares Full Year Fully Franked Dividend for the Fiscal Year 2023, Payable on 3 October 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of AU$0.07 per share at 13% yield

Price target increased by 7.1% to AU$4.03

First half 2023 earnings released: EPS: AU$0.13 (vs AU$0.65 in 1H 2022)

Australian Clinical Labs Limited Announces Dividend for the Six Months Ended December 31, 2022, Payable on April 26, 2023

Investor sentiment improves as stock rises 16%

Price target decreased by 8.5% to AU$3.76

Price target decreased to AU$4.27

High number of new and inexperienced directors

Price target decreased to AU$4.62

Independent Non-Executive Director recently sold AU$71k worth of stock

Australian Clinical Labs Limited Announces Resignation of Dr. Michael Stanford as Non-Executive Director

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2023

Independent Non-Executive Director recently sold AU$140k worth of stock

Upcoming dividend of AU$0.41 per share

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$5.30

Australian Clinical Labs Limited Declares Dividend for the Period of Six Months Ended 30 June 2022

Investor sentiment deteriorated over the past week

CEO & Executive Director recently bought AU$335k worth of stock

High number of new and inexperienced directors

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Declares Ordinary Dividend for the Period of Six Months December 31, 2021, Payable April 21, 2022

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Australian Clinical Labs Limited Revises Earnings Guidance for the First Half 2022

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Investor sentiment improved over the past week

Consensus EPS estimates increase by 46%

Australian Clinical Labs Limited (ASX:ACL) completed the acquisition of Medlab Pathology Pty Ltd.

Independent Non-Executive Director recently bought AU$99k worth of stock

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Full year 2021 earnings released: EPS AU$0.40 (vs AU$0.28 in FY 2020)

Australian Clinical Labs Limited Provides Earnings Guidance for the Fiscal Year of 2021

Australian Clinical Labs Limited has completed an IPO in the amount of AUD 408.559209 million.

Stabilité et croissance des paiements

Rendement des dividendes par rapport au marché

Bénéfice distribué aux actionnaires

Paiement en espèces aux actionnaires

Découvrir des entreprises qui versent des dividendes élevés